BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37248147)

  • 1. Does the Gleason Score 7 Upgrading Always Predict Worse Prognosis?
    Zhou J; Yu M; Ding J; Qi J
    Clin Genitourin Cancer; 2023 Dec; 21(6):e412-e421. PubMed ID: 37248147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: results from a single institution series.
    Tilki D; Schlenker B; John M; Buchner A; Stanislaus P; Gratzke C; Karl A; Tan GY; Ergün S; Tewari AK; Stief CG; Seitz M; Reich O
    Urol Oncol; 2011; 29(5):508-14. PubMed ID: 19837614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How significant is upgrade in Gleason score between prostate biopsy and radical prostatectomy pathology while discussing less invasive treatment options?
    Suer E; Gokce MI; Gulpinar O; Guclu AG; Haciyev P; Gogus C; Turkolmez K; Baltaci S
    Scand J Urol; 2014 Apr; 48(2):177-82. PubMed ID: 23941315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
    Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Discrepancy between Needle Biopsy and Radical Prostatectomy Gleason Score in Patients with Prostate Cancer.
    Abedi AR; Basiri A; Shakhssalim N; Sadri G; Ahadi M; Hojjati SA; Sheykhzadeh S; Askarpour S; Ghiasy S
    Urol J; 2020 Aug; 18(4):395-399. PubMed ID: 32798231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Pathologic Upgrading of Gleason Score 7 Prostate Cancer on the Risk of the Biochemical Recurrence after Radical Prostatectomy.
    Park J; Yoo S; Cho MC; Cho MH; Jeong CW; Ku JH; Kwak C; Kim HH; Jeong H
    Biomed Res Int; 2018; 2018():4510149. PubMed ID: 29854755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinically predictive factors of Gleason score upgrading in patients after radical prostatectomy].
    Zuo Q; Zhang F; Huang Y; Ma LL; Lu M; Lu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):603-606. PubMed ID: 29263497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.
    Epstein JI; Feng Z; Trock BJ; Pierorazio PM
    Eur Urol; 2012 May; 61(5):1019-24. PubMed ID: 22336380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.
    Altok M; Troncoso P; Achim MF; Matin SF; Gonzalez GN; Davis JW
    Asian J Androl; 2019; 21(6):598-604. PubMed ID: 31115364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort.
    Zhang B; Wu S; Zhang Y; Guo M; Liu R
    Cancer Med; 2021 Nov; 10(21):7772-7780. PubMed ID: 34528767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of >/=8.
    Manoharan M; Bird VG; Kim SS; Civantos F; Soloway MS
    BJU Int; 2003 Oct; 92(6):539-44. PubMed ID: 14511029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of PSA velocity in predicting pathologic upgrade for Gleason 6 prostate cancer.
    Krane LS; Menon M; Kaul SA; Siddiqui SA; Wambi C; Peabody JO; Agarwal PK
    Urol Oncol; 2011; 29(4):372-7. PubMed ID: 19576796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Woo S; Kim SY; Lee J; Kim SH; Cho JY
    Eur Radiol; 2016 Oct; 26(10):3580-7. PubMed ID: 26847042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6.
    Santok GD; Abdel Raheem A; Kim LH; Chang K; Lum TG; Chung BH; Choi YD; Rha KH
    Investig Clin Urol; 2017 Mar; 58(2):90-97. PubMed ID: 28261677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma IL-6 and TNF-α levels correlate significantly with grading changes in localized prostate cancer.
    Zhou J; Chen H; Wu Y; Shi B; Ding J; Qi J
    Prostate; 2022 Apr; 82(5):531-539. PubMed ID: 35037273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.